In an effort to provide you with timely market feedback from the 2016 ASCO Annual Meeting, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ conducted immediately after the meeting. This report explores presentations concerning the sidedness of the primary tumor in metastatic colorectal cancer(mCRC) and the potential use of gemcitabine + capecitabine (GEMCAP) as adjuvant therapy in resected pancreatic cancer patients.
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, VP, Research and Physician Society, and Jan Heybroek, President MDoutlook
You must be logged in to post a comment